

1133

Narimoto K¹, Yamaguchi A¹, Kato C¹, Takeyama M¹, Kawaguchi S², Kuribayashi M², Izumi K², Kitagawa Y², Namiki M²

1. Senboku Fujii Hospital, 2. Kanazawa University

TENSION-FREE VAGINAL MESH PROCEDURE FOR PELVIC ORGAN PROLAPSE: THE EXPERIENCE OF 158 CASES

Hypothesis / aims of study

To evaluate the efficacy and the changes in symptoms of overactive bladder (OAB) using tension-free vaginal mesh (TVM) procedure on pelvic organ prolapsed

Study design, materials and methods

Between October 2005 and March 2010, 158 patients with POP underwent TVM procedure at our hospital. Mean age was 67.8 years (range 39-86). 34 patients (21.5%) had undergone hysterectomy. Prolapse assessment was measured according to the pelvic organ prolapse quantization system. All patients had a symptomatic cystocele > stage 2 according to POP-Q stage. A mesh was cut to a same size to cover the whole POP. Forty two patients underwent anterior TVM, and three underwent posterior TVM. Ninety two patients underwent both anterior and posterior, twenty one patients underwent complete TVM procedure. Operation time was 86.2, 84.3, 119.5, 117.1 minutes respectively. Each patient was assessed at 1, 3, 6, 12 months after surgery. Urinary function after TVM was also assessed by using uroflowmetry and overactive bladder symptom score (OABSS).

Results

Perioperative complications were the following: five bladder injuries (3.2%), no rectal injuries and four hemorrhages greater than 500 mL (2.3%). Mesh erosion was detected in four patients (2.5%). Using our definition of success based on anatomic outcomes, the overall cure and improvement rate was 97.5% (asymptomatic with no or stage 2 pelvic organ prolapse).

Urodynamics showed that voiding function has objective improvement. Questionnaire results of postoperative OAB symptoms revealed a significant improvement.

Concluding message

TVM procedure seems to be an excellent procedure in the definitive surgical treatment of POP. This procedure is simple, mini-invasive, reproducible and efficient with low morbidity and good tolerance.

| | |
|---|--|
| <i>Specify source of funding or grant</i> | None |
| <i>Is this a clinical trial?</i> | No |
| <i>What were the subjects in the study?</i> | HUMAN |
| <i>Was this study approved by an ethics committee?</i> | Yes |
| <i>Specify Name of Ethics Committee</i> | kanazawa university graduate school of medical science |
| <i>Was the Declaration of Helsinki followed?</i> | Yes |
| <i>Was informed consent obtained from the patients?</i> | Yes |